The non-small cell lung cancer clinical trial analysis report delivers important insights into ongoing research of 120+ ...
Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients ...
Canadians swallow millions of pills every day to treat common health issues like high blood pressure, high cholesterol and ...
A few transplant patients in a small study were able to stop using immunosuppressive drugs, thanks to pre-transplant cell ...
Clinical trial collaboration and supply agreement between Boehringer and BioNTech to conduct a Phase Ib/II clinical trial to explore complementary immuno-oncology mechanisms in extensive‑stage small ...
Boehringer Ingelheim and Zai Lab launch a clinical collaboration to evaluate a dual DLL3‑targeting combination therapy in small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs).
Results of a new study conclude that a pathology tool powered by artificial intelligence can predict whether a patient with ...
McGill University researchers have developed an artificial intelligence tool that can identify small groups of cells most responsible for driving aggressive cancers. The tool, called SIDISH, offers ...
The KRAS p.G12D variant occurs in 5% of patients with non–small-cell lung cancer (NSCLC) and is the most common substitution variant in pancreatic ductal adenocarcinoma, occurring in 40% of patients, ...
The results suggest the drug boasts similar safety and efficacy in non-small cell lung cancer compared with the field’s ...
Cell cultures—single layers of cells grown in a small dish—have enabled researchers to study biological growth, develop or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results